Search results for "Cannabi"

showing 10 items of 489 documents

Altered endocannabinoid-dynamics in craniopharyngioma patients and their association with HPA-axis disturbances.

2021

Objective Patients with craniopharyngioma (CP) frequently suffer from morbid obesity. Endocannabinoids (ECs) are involved in weight gain and rewarding behavior but have not been investigated in this context. Design Cross-sectional single-center study. Methods Eighteen patients with CP and 16 age- and sex-matched controls were included. Differences in endocannabinoids (2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (AEA)) and endocannabinoid-like molecules (oleoyl ethanolamide (OEA), palmitoylethanolamide (PEA), and arachidonic acid (AA) were measured at baseline and following endurance exercise. We further explored ECs-dynamics in relation to markers of HPA-axis activity (ACT…

AdultMalemedicine.medical_specialtyHypothalamo-Hypophyseal SystemHydrocortisonePolyunsaturated AlkamidesEndocrinology Diabetes and MetabolismHypothalamusContext (language use)Oleic AcidsArachidonic AcidsGlycerideschemistry.chemical_compoundCraniopharyngiomaYoung AdultEndocrinologyCopeptinAdrenocorticotropic HormoneEndurance trainingInternal medicinemedicineEthanolamideHumansPituitary NeoplasmsExerciseArachidonic Acidbusiness.industryGlycopeptidesGeneral MedicineMiddle Agedmedicine.diseaseEndocannabinoid systemCraniopharyngiomaEndurance TrainingEndocrinologyCross-Sectional StudieschemistryCase-Control StudiesArachidonic acidFemalemedicine.symptombusinessWeight gainEndocannabinoidsEuropean journal of endocrinology
researchProduct

Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users.

2012

Background Cannabis use is associated with an increased risk of psychosis. One study has suggested that genetic variation in the AKT1 gene might influence this effect. Methods In a case-control study of 489 first-episode psychosis patients and 278 control subjects, we investigated the interaction between variation at the AKT1 rs2494732 single nucleotide polymorphism and cannabis use in increasing the risk of psychosis. Results The rs2494732 locus was not associated with an increased risk of a psychotic disorder, with lifetime cannabis use, or with frequency of use. We did, however, find that the effect of lifetime cannabis use on risk of psychosis was significantly influenced by the rs24947…

AdultMalemedicine.medical_specialtyPsychosisMarijuana AbuseEpisode of CarePolymorphism Single NucleotideRisk AssessmentOddsInternational Classification of DiseasesRisk FactorsLondonSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.medicineConfidence IntervalsOdds RatioHumansGenetic Predisposition to DiseaseGenetic TestingGene–environment interactionPsychiatrySettore MED/25 - PsichiatriaBiological PsychiatryDemographybiologyCase-control studyOdds ratiomedicine.diseasebiology.organism_classificationConfidence intervalPsychotic DisordersSocioeconomic FactorsCase-Control StudiesFemaleGene-Environment InteractionAKT1 gene cannabis use gene environment interaction psychosis schizophrenia signaling pathwaysCannabisRisk assessmentPsychologyProto-Oncogene Proteins c-aktDemographyBiological psychiatry
researchProduct

Cannabis users have higher premorbid IQ than other patients with first onset psychosis.

2013

Background: A number of studies have reported that patients with psychosis who use cannabis have better cognitive performance than those who do not. This is surprising as cannabis can impair cognition in healthy subjects. An obvious question is whether the better current performance of psychotic patients who have used cannabis is a reflection of their having a higher premorbid IQ than those psychotic patients who haven't used cannabis. Aim: In a sample of patients at their first episode of psychosis, we tested the hypothesis that patients who smoked cannabis would have a higher premorbid IQ than patients who did not. Methodology: 279 participants (119 patients and 160 healthy controls) were…

AdultMalemedicine.medical_specialtyPsychosisMarijuana AbuseFirst Episode of Psychosis (FEP)Premorbid IQIntelligenceNeuropsychological TestsSubstance usebehavioral disciplines and activitiesYoung AdultCognitionSettore M-PSI/08 - Psicologia Clinicamental disordersmedicineHumansEffects of sleep deprivation on cognitive performanceCannabiYoung adultCannabis; Cognition; First Episode of Psychosis (FEP); IQ; Premorbid IQ; Risk of psychosis; Schizophrenia; Substance useRisk of psychosiPsychiatryBiological PsychiatryFirst episodeIntelligence TestsPsychiatric Status Rating ScalesAnalysis of VarianceChi-Square DistributionIntelligence quotientbiologymedicine.diseasebiology.organism_classificationPsychiatry and Mental healthPsychotic DisordersSchizophreniaIQSchizophreniaFemaleCannabisPsychologyhuman activitiesChi-squared distributionClinical psychology
researchProduct

Soothing the seizures of children.

2008

Endocannabinoids are versatile molecules, regulating a variety of functions in the body. Daniele Piomelli explores how recent clinical trials testing rimonabant, an inhibitor of endocannabinoid signaling, for weight loss emerged from studies of individuals with schizophrenia; such trials have spurred basic research into how endocannabinoids affect both energy use and mood. Beat Lutz and Krisztina Monory examine how rimonabant might prove useful for preventing the development of adult epilepsy in response to fever-induced seizures in infants and young children.

AdultModels NeurologicalGeneral Biochemistry Genetics and Molecular BiologySeizures FebrileEpilepsyRimonabantPiperidinesBasic researchWeight lossCannabinoid Receptor ModulatorsmedicineHumansCannabinoid Receptor AntagonistsClinical Trials as TopicEpilepsybusiness.industryGeneral Medicinemedicine.diseaseEndocannabinoid systemClinical trialMoodChild PreschoolCannabinoid receptor antagonistPyrazoleslipids (amino acids peptides and proteins)medicine.symptomRimonabantbusinessNeurosciencemedicine.drugNature medicine
researchProduct

Association of a CB1 Cannabinoid Receptor Gene (CNR1) polymorphism with severe alcohol dependence

2002

Abstract Due to the involvement of the endogenous cannabinoid system in brain reward mechanisms a silent polymorphism (1359G/A; Thr453Thr) in the single coding exon of the CB1 human cannabinoid receptor gene ( CNR1 ) was analysed in 121 severely affected Caucasian alcoholics and 136 most likely non-alcoholic controls. The observed frequency of the A allele was 31.2% for controls and 42.1% for alcoholics with severe withdrawal syndromes ( P =0.010). Post-hoc exploration indicated that this allelic association resulted from an excess of the homozygous A/A genotype in patients with a history of alcohol delirium ( P =0.031, DF 2), suggesting s an increased risk of delirium (OR=2.45, 95% CI 1.14…

Adultmedicine.medical_specialtyCannabinoid receptorGenotypeReceptors DrugToxicologyAlcohol Withdrawal SeizuresAlcohol Withdrawal DeliriumExonRisk FactorsPolymorphism (computer science)Internal medicinemental disordersGenotypemedicineHumansPharmacology (medical)AlleleReceptors CannabinoidPharmacologyPolymorphism Geneticbusiness.industryAlcohol Withdrawal DeliriumAlcoholismPsychiatry and Mental healthEndocrinologyDeliriumBrain stimulation rewardmedicine.symptombusinessDrug and Alcohol Dependence
researchProduct

A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice

2010

BACKGROUND: Parkinson's disease (PD), the second most frequent neurodegenerative disorder at old age, can be caused by elevated expression or the A53T missense mutation of the presynaptic protein alpha-synuclein (SNCA). PD is characterized pathologically by the preferential vulnerability of the dopaminergic nigrostriatal projection neurons. METHODOLOGY/PRINCIPAL FINDINGS: Here, we used two mouse lines overexpressing human A53T-SNCA and studied striatal dysfunction in the absence of neurodegeneration to understand early disease mechanisms. To characterize the progression, we employed young adult as well as old mice. Analysis of striatal neurotransmitter content demonstrated that dopamine (DA…

AgingDopaminelcsh:MedicineMicechemistry.chemical_compoundHomer Scaffolding ProteinsReceptor Cannabinoid CB1lcsh:ScienceLong-term depressionNeurotransmitterChromatography High Pressure LiquidIn Situ Hybridization FluorescenceOligonucleotide Array Sequence AnalysisMice KnockoutNeuronal PlasticityMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionDopaminergicNeurodegenerationGenetics and Genomics/Gene ExpressionElectrophysiologyalpha-SynucleinResearch ArticleRadioimmunoprecipitation Assaymedicine.medical_specialtyNeuronal Calcium-Sensor ProteinsHOMER1Substantia nigraNeurotransmissionBiologyNeurological DisordersInternal medicinemedicineAnimalsHumansddc:610Cyclic Nucleotide Phosphodiesterases Type 7Activating Transcription Factor 2lcsh:RNeuropeptidesmedicine.diseaseMolecular biologyCorpus StriatumMice Mutant StrainsEndocrinologyGenetics and Genomics/Disease ModelschemistrySynaptic plasticitylcsh:QCarrier ProteinsPLoS ONE
researchProduct

Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid de…

2012

Alzheimer's disease (AD) is characterized by amyloid-beta deposition in amyloid plaques, neurofibrillary tangles, inflammation, neuronal loss, and cognitive deficits. Cannabinoids display neuromodulatory and neuroprotective effects and affect memory acquisition. Here, we studied the impact of cannabinoid receptor type 1 (CB1) deficiency on the development of AD pathology by breeding amyloid precursor protein (APP) Swedish mutant mice (APP23), an AD animal model, with CB1-deficient mice. In addition to the lower body weight of APP23/CB1(-/-) mice, most of these mice died at an age before typical AD-associated changes become apparent. The surviving mice showed a reduced amount of APP and its …

Agingmedicine.medical_specialtyPathologyCannabinoid receptormedicine.medical_treatmentMutantMice TransgenicInflammationDiseaseNeuroprotectionAmyloid beta-Protein PrecursorMiceReceptor Cannabinoid CB1Alzheimer DiseaseCell Line TumorInternal medicinemental disordersmedicineAmyloid precursor proteinAnimalsHumansMaze LearningCognitive impairmentAmyloid beta-Peptidesbiologybusiness.industryGeneral NeuroscienceBody WeightAge FactorsBrainPeptide FragmentsDisease Models AnimalEndocrinologyGene Expression RegulationMutationbiology.proteinlipids (amino acids peptides and proteins)MicrogliaNeurology (clinical)CannabinoidGeriatrics and Gerontologymedicine.symptomCognition DisordersbusinessDevelopmental BiologyNeurobiology of Aging
researchProduct

Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: study on electrophysiological and behavioral mod…

2015

A growing bulk of evidence suggests that cannabinoid system plays a pivotal role in the control of hyperexcitability phenomena. Notwithstanding, the anticonvulsant action of cannabinoids has not been fully addressed, in particular the involvement of potential cellular neuromodulators, for instance nitric oxide. In the current study, we focused on two distinct rat models of temporal lobe epilepsy, the Maximal Dentate Activation and the pilocarpine-induced acute seizures, providing both electrophysiological and behavioral data on cannabinoid and nitrergic system interplay. We evaluated the antiepileptic effects of WIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4- morpholinylmethyl) pyrrolo[1,…

AgonistAM251MaleCannabinoid receptorIndazolesmedicine.drug_classmedicine.medical_treatmentMorpholinesHippocampusPharmacologyNaphthalenesNitric OxideHippocampusSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1medicineAnimalshippocampus temporal lobe epilepsy cannabinoids behavior percentage of protection electrophysiology.Rats WistarWIN 55212-2Cannabinoid Receptor AgonistsDose-Response Relationship DrugCannabinoidsGeneral NeurosciencePilocarpinemedicine.diseaseEndocannabinoid systemBenzoxazinesRatsDisease Models AnimalEpilepsy Temporal LobePyrazolesCannabinoidNitric Oxide SynthasePsychologyNeurosciencemedicine.drug
researchProduct

Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat.

2009

The anticonvulsant effect of cannabinoids (CB) has been shown to be mediated by the activation of the CB(1) receptor. This study evaluates the anticonvulsant activity of (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone (WIN55,212-2, CB agonist) alone or preceded by the administration of N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, selective CB(1) antagonist) in an experimental in vivo model of complex partial seizures (maximal dentate gyrus activation - MDA) in the rat. WIN55,212-2 (21mgkg(-1)) exerted an anticonvulsant effect, significantly reduced by the pre-treatme…

AgonistAM251Malemedicine.medical_specialtyCannabinoid receptormedicine.drug_classmedicine.medical_treatmentMorpholinesNaphthalenesSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1Internal medicineControlCannabinoid Receptor ModulatorsmedicineAnimalsRats WistarReceptorEpilepsyChemistryCannabinoidsGeneral NeuroscienceAntagonistBrainmedicine.diseaseCalcium Channel BlockersElectric StimulationBenzoxazinesRatsDisease Models AnimalMaximal dentate activationAnticonvulsantEndocrinologySettore BIO/14 - FarmacologiaRatPyrazolesAnticonvulsantsCannabinoidEpilepsies Partialmedicine.drugNeuroscience letters
researchProduct

Effects of Cannabinoid Exposure during Adolescence on the Conditioned Rewarding Effects of WIN 55212-2 and Cocaine in Mice: Influence of the Novelty-…

2016

Adolescent exposure to cannabinoids enhances the behavioural effects of cocaine, and high novelty-seeking trait predicts greater sensitivity to the conditioned place preference (CPP) induced by this drug. Our aim was to evaluate the influence of novelty-seeking on the effects of adolescent cannabinoid exposure. Adolescent male mice were classified as high or low novelty seekers (HNS and LNS) in the hole-board test. First, we evaluated the CPP induced by the cannabinoid agonist WIN 55212-2 (0.05 and 0.075 mg/kg, i.p.) in HNS and LNS mice. Then, HNS and LNS mice were pretreated i.p. with vehicle, WIN 55212-2 (0.1 mg/kg), or cannabinoid antagonist rimonabant (1 mg/kg) and were subsequently con…

AgonistMaleArticle Subjectmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectMorpholinesConditioning ClassicalPharmacologyNaphthaleneslcsh:RC321-57103 medical and health sciencesMice0302 clinical medicineRimonabantCocaineRewardmedicineAnimalslcsh:Neurosciences. Biological psychiatry. Neuropsychiatrymedia_commonCannabinoid Receptor AgonistsAddictionAntagonistNovelty seekingCannabinoid Receptor AgonistsConditioned place preference030227 psychiatryBenzoxazinesNeurologyExploratory BehaviorNeurology (clinical)CannabinoidPsychologyCorrigendum030217 neurology & neurosurgeryResearch Articlemedicine.drugNeural plasticity
researchProduct